N-of-One Selected to Provide Interpretation Services for Spectrum'sTumor Panel
News Aug 19, 2015
Spectrum Health is a not-for-profit health system offering a full continuum of care through the Spectrum Health Hospital Group, which is comprised of 12 hospitals. It is the largest cancer care provider in West Michigan. Financial terms of the agreement are not disclosed.
The Spectrum Health Cancer Center is focused on delivering individualized care to each cancer patient. A commitment to high-quality care and innovation has made Spectrum Health a regional leader and a referral center for cancer treatment.
“This is a wonderful opportunity for the Spectrum Health Cancer Center to expand our ability to provide personalized care and targeted therapies for our patients,” said Dr. Judy L. Smith, Chief of Oncology, Spectrum Health.
N-of-One’s clinical interpretation provides the relevant scientific and clinical evidence related to the mutation profile of a tumor identified by sequencing, taking into account each patient’s specific molecular profile. This in turn links the clinical and scientific evidence to therapeutic strategies relevant for each patient.
“N-of-One’s clinical interpretation provides Spectrum Health with high-quality evidence and analysis that enables us to help physicians identify the best possible therapeutic strategies for their cancer patients,” said Dr. Cong Liu, Molecular Diagnostics Director at Spectrum Health. “This is a highly cost effective and efficient way for us to stay up-to-date on state-of-the art findings that are applicable to each patient.”
“N-of-One is very pleased to be working closely with Spectrum Health to deliver best-in-class, patient-specific clinical and scientific analysis that will support the pathologists in preparing Spectrum Health’s clinical reports”, said Chris Cournoyer, CEO at N-of-One. “Our objective is to provide high-quality. patient-specific clinical interpretation evidence at a cost-effective price.”
Blood Test Rapidly Detects Signs of Pancreatic CancerNews
The new test can rapidly screen a drop of blood for biomarkers of pancreatic cancer, and provide results in less than an hour.READ MORE
Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing SitesNews
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.READ MORE
Plug-and-Play Diagnostic Devices DevelopedNews
Researchers at MIT’s Little Devices Lab have developed a set of modular blocks that can be put together in different ways to produce diagnostic devices. These “plug-and-play” devices, which require little expertise to assemble, can test blood glucose levels in diabetic patients or detect viral infection, among other functions.READ MORE
Comments | 0 ADD COMMENT
World Congress on Bio-organic and Medicinal Chemistry
Nov 12 - Nov 13, 2018